JP2004536829A5 - - Google Patents

Download PDF

Info

Publication number
JP2004536829A5
JP2004536829A5 JP2003508337A JP2003508337A JP2004536829A5 JP 2004536829 A5 JP2004536829 A5 JP 2004536829A5 JP 2003508337 A JP2003508337 A JP 2003508337A JP 2003508337 A JP2003508337 A JP 2003508337A JP 2004536829 A5 JP2004536829 A5 JP 2004536829A5
Authority
JP
Japan
Prior art keywords
tablet
pseudoephedrine
cetirizine
tablet according
segment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003508337A
Other languages
English (en)
Japanese (ja)
Other versions
JP4041460B2 (ja
JP2004536829A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/006342 external-priority patent/WO2003002098A1/en
Publication of JP2004536829A publication Critical patent/JP2004536829A/ja
Publication of JP2004536829A5 publication Critical patent/JP2004536829A5/ja
Application granted granted Critical
Publication of JP4041460B2 publication Critical patent/JP4041460B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003508337A 2001-06-28 2002-06-10 セチリジン及びプソイドエフェドリンを含む錠剤 Expired - Fee Related JP4041460B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30125001P 2001-06-28 2001-06-28
EP01115807 2001-06-28
PCT/EP2002/006342 WO2003002098A1 (en) 2001-06-28 2002-06-10 Tablet comprising cetirizine and pseudoephedrine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007092969A Division JP2007176958A (ja) 2001-06-28 2007-03-30 セチリジン及びプソイドエフェドリンを含む錠剤

Publications (3)

Publication Number Publication Date
JP2004536829A JP2004536829A (ja) 2004-12-09
JP2004536829A5 true JP2004536829A5 (enExample) 2006-08-24
JP4041460B2 JP4041460B2 (ja) 2008-01-30

Family

ID=56290291

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003508337A Expired - Fee Related JP4041460B2 (ja) 2001-06-28 2002-06-10 セチリジン及びプソイドエフェドリンを含む錠剤

Country Status (22)

Country Link
EP (1) EP1404304B1 (enExample)
JP (1) JP4041460B2 (enExample)
KR (1) KR100926410B1 (enExample)
CN (1) CN100490809C (enExample)
AT (1) ATE432068T1 (enExample)
AU (1) AU2002345024B2 (enExample)
BR (1) BR0210650A (enExample)
CA (1) CA2451519C (enExample)
CZ (1) CZ20033454A3 (enExample)
DK (1) DK1404304T3 (enExample)
EE (1) EE05357B1 (enExample)
ES (1) ES2324769T3 (enExample)
HU (1) HU229803B1 (enExample)
MX (1) MXPA03010430A (enExample)
NZ (1) NZ530289A (enExample)
PL (1) PL206069B1 (enExample)
PT (1) PT1404304E (enExample)
RO (1) RO122476B1 (enExample)
RU (1) RU2286784C2 (enExample)
SI (1) SI1404304T1 (enExample)
SK (1) SK287645B6 (enExample)
WO (1) WO2003002098A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20031057B1 (hr) * 2001-06-28 2013-05-31 Ucb Farchim Sa, Z.I. Planchy Tableta koja sadrži cetirizin i pseudoefedrin
KR100698400B1 (ko) 2004-04-14 2007-03-23 이은주 탈모증 및 전립선비대증 치료를 위한 약제학적 조성물
US20100172984A1 (en) * 2006-06-06 2010-07-08 Bijay Kumar Padhi tablet dosage form comprising cetirizine and pseudoephedrine
US9408816B2 (en) * 2006-12-26 2016-08-09 Pharmacyclics Llc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
US8439033B2 (en) 2007-10-09 2013-05-14 Microdose Therapeutx, Inc. Inhalation device
CN105381524A (zh) 2010-01-05 2016-03-09 微剂量治疗技术公司 吸入设备和方法
KR101193495B1 (ko) 2010-02-01 2012-10-23 한미사이언스 주식회사 슈도에페드린 및 레보세티리진을 포함하는 경구용 복합 조성물
JP5781606B2 (ja) 2010-06-16 2015-09-24 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド インフルエンザ、一般的な感冒および炎症の治療におけるレボセチリジンおよびモンテルカストの使用
CN102302497A (zh) * 2011-05-18 2012-01-04 天圣制药集团股份有限公司 一种治疗过敏性鼻炎的制剂及其制备方法
KR20130009553A (ko) 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
KR101892788B1 (ko) 2011-09-13 2018-08-28 파마싸이클릭스 엘엘씨 벤다무스틴과 조합된 히스톤 디아세틸라제 억제제의 제제 및 그의 용도
KR101372324B1 (ko) * 2012-02-09 2014-03-13 동국대학교 경주캠퍼스 산학협력단 알러지성 비염 치료를 위한 한방 치료제 및 슈도에페드린을 함유한 복합서방형의 약제학적 조성물
EP3300734B1 (en) 2013-03-13 2019-08-14 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
JP6313414B2 (ja) 2013-03-13 2018-04-18 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 外傷性傷害の処置におけるレボセチリジン及びモンテルカストの使用
AU2014249534B2 (en) 2013-03-13 2018-08-30 IRR, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
WO2016140630A1 (en) 2015-03-05 2016-09-09 PHARMACTIVE ILAÇ SANAYI VE TlCARET A. Ş. An effervescent composition comprising levocetirizine and pseudoephedrine
EP4099977A1 (en) * 2020-02-03 2022-12-14 Johnson & Johnson Consumer Inc. A single layer chewable tablet comprising cetirizine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469009B1 (en) * 1996-04-08 2002-10-22 Ucb, S.A. Pharmaceutical compositions for the treatment of rhinitis
EP0811374A1 (en) * 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
BE1011045A3 (fr) * 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
US6267986B1 (en) * 1999-09-24 2001-07-31 Ranbaxy Laboratories Limited Process for the preparation of a controlled drug delivery system containing pseudoephedrine and a long acting antihistamine

Similar Documents

Publication Publication Date Title
JP2004536829A5 (enExample)
US20220062276A1 (en) Pharmaceutical compositions
EP1755561B1 (en) Multi-layer tablet comprising non-steroidal anti-inflammatory drugs decongestants and non-sedating antihistamines
CA2918576C (en) Immediate release analgesic and antiemetic combination compositions
HUP0204079A2 (hu) Szedatív hatástól mentes antihisztaminok és leukotrién hatást befolyásoló anyagok új kombinációja orrnyálkahártya-gyulladás, vagy kötőhártya-gyulladás kezelésére
CA2661759A1 (en) Buprenophine-wafer for drug substitution therapy
EP3678648B1 (en) Methods of using dipivefrin
CN105431144A (zh) 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
KR100926410B1 (ko) 세티리진 및 슈도에페드린을 포함하는 정제
JP2006518731A5 (enExample)
CA2508611A1 (en) Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
KR101512386B1 (ko) 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법
JP2005512946A5 (enExample)
KR20090037347A (ko) HMG-CoA 환원효소억제제와 담즙산을 포함하는 C형 간염 치료용 약학조성물
ZA200309720B (en) Tablet comprising cetirizine and pseudoephedrine
CN103249415B (zh) 包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法
EP2830605B1 (en) A combination medicament comprising phenylephrine and paracetamol
US20210283096A1 (en) Methods of treating obesity in responder and non-responder populations
KR101816726B1 (ko) 베포타스틴 함유 방출제어형 정제
WO2010038240A9 (en) Pharmaceutical composition comprising nimesulide and levocetirizine
EP1569651B1 (en) Tablet comprising efletirizine and pseudoephedrine
CN111655263A (zh) 稳定的含硫胺素的药物制剂
KR101591357B1 (ko) 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법
KR20200048516A (ko) 복합제 의약 조성물
KR20180130682A (ko) 베포타스틴 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 제제